GEMoaB Monoclonals

Edit links
From Wikipedia, the free encyclopedia

GEMoaB Monoclonals
Company typeGmbH
IndustryBiotechnology
Pharmaceutical
Founded2011
FounderGerhard Ehninger, Michael Bachmann
HeadquartersDresden, Germany
Key people
Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger (CMO)[1]
ProductsGEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA
Revenuen.a.
Websitewww.gemoab.com

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[2] [3] It was acquired by the new company AvenCell Therapeutics in 2021.[4][5]


Company background[edit]

See also: Chimeric antigen receptor T cell

To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[6]

Scientific and strategic board[edit]

The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).[7]

Co-operations[edit]

Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[8]

Drugs currently under development[edit]

  • GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[9][10]
  • GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[11]
  • UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
  • UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours

Literatur[edit]

  • Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141. doi:10.1038/s41598-020-59082-4, PMID 32034289.
  • Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. doi:10.1182/blood-2018-99-113288.
  • Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. doi:10.1080/2162402X.2019.1659095, PMID 31646084.
  • C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967, doi:10.1038/leu.2013.18, PMID 23325142.

See also[edit]

References[edit]

  1. ^ Leadership Team Leadership Team, Company Website, Retrieved: July 15, 2021
  2. ^ Get to know GEMoaB, Company Website, Retrieved: May 11, 2020
  3. ^ "GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias". chemie-link.de. 9 March 2020. Retrieved 11 May 2020.
  4. ^ "Clinical-stage biopharma company targets hard-to-treat cancers". AvenCell. Retrieved 12 February 2024.
  5. ^ "Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company". Blackstone. 22 June 2021. Retrieved 12 February 2024.
  6. ^ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S. e458, doi:10.1038/bcj.2016.61, PMID 27518241, PMC 5022178.
  7. ^ Scientific and Strategic Advisory Board, Company Website, Retrieved: May 11, 2020
  8. ^ Our Partners, Company Website, Retrieved: May 11, 2020
  9. ^ AML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020
  10. ^ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020
  11. ^ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=GEMoaB_Monoclonals&oldid=1206649254"